Capitalizing on the 4th Wave of Oncology Innovation

A new generation of immune-driven treatment modalities, spanning allogeneic and in vivo CAR-T therapies, trispecific antibodies, and cancer vaccines, is transforming how cancer is targeted and controlled. But which will stand out from the pack and lead the charge? These innovations promise to extend therapeutic benefit, improve durability of response, and deliver unprecedented precision at the cellular level. However, to succeed, manufacturers must combine their scientific discovery with a nuanced understanding of the immune system and how to harness it effectively.

In this white paper, we explore how biopharma leaders can navigate this complexity, evaluating emerging modalities, prioritizing investments, and positioning their portfolios to win in an increasingly competitive and rapidly evolving oncology landscape.